Optimum timing of treatment for hepatitis C infection relative to liver transplantation  Dr Audrey Coilly, MD, Bruno Roche, MD, Prof Jean-Charles Duclos-Vallée, MD, Prof Didier Samuel, MD  The Lancet Gastroenterology & Hepatology  Volume 1, Issue 2, Pages 165-172 (October 2016) DOI: 10.1016/S2468-1253(16)30008-5 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Strategies to prevent recurrence of HCV infection in liver transplant recipients Horizontal lines indicate relative timing scales. HCV=hepatitis C virus. SVR=sustained virological response. *Treatment duration should take into account the expected time on the liver transplantation waiting list. †HCV always recurs in patients who have HCV RNA detectable in serum at the time of transplantation. The Lancet Gastroenterology & Hepatology 2016 1, 165-172DOI: (10.1016/S2468-1253(16)30008-5) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Proposed decision algorithm to treat patients on waiting list HCC=hepatocellular carcinoma. ESLD=end-stage liver disease. CP=Child-Pugh. LT=liver transplantation. MELD=Model for End-Stage Liver Disease. *Taking into account system of allocation, possible improvement, clinical and biological factors, and quality of life. The Lancet Gastroenterology & Hepatology 2016 1, 165-172DOI: (10.1016/S2468-1253(16)30008-5) Copyright © 2016 Elsevier Ltd Terms and Conditions